دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
دانلود کتاب Advances in Psoriasis. A Multisystemic Guide
دانلود کتاب پیشرفت در پسوریازیس راهنمای چند سیستمی
مشخصات کتاب
Advances in Psoriasis. A Multisystemic Guide
ویرایش: 2 نویسندگان: Jeffrey M. Weinberg, Mark Lebwohl سری: ISBN (شابک) : 9783030548582, 9783030548599 ناشر: Springer سال نشر: 2012 تعداد صفحات: 415 زبان: English فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) حجم فایل: 10 مگابایت
قیمت کتاب (تومان) : 52,000
در صورت تبدیل فایل کتاب Advances in Psoriasis. A Multisystemic Guide به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب پیشرفت در پسوریازیس راهنمای چند سیستمی نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
توضیحاتی درمورد کتاب به خارجی
فهرست مطالب
Contents 1: Introduction to and History of Psoriasis and Psoriasis Therapy History of Psoriasis Identification of Psoriasis as a Unique Disease History of the Treatment of Psoriasis Arsenic, Ammoniated Mercury and Chrysarobin Anthralin and Tar Corticosteroids Methotrexate and PUVA Narrowband UVB, Retinoids, Vitamin D Systemic Immunosuppressive Medications 2: Pathophysiology of Psoriasis/Novel Pathways Principles of Immunity Implicating Dysregulation of Immunity Intralesional T Lymphocytes T-Lymphocyte Stimulation T-Lymphocyte Signaling NK T Cellss Dendritic Cells Cytokines Tumor Necrosis Factor α IL-23/TH17 Axis Genetic Basis of Psoriasis Conclusion References 3: Psoriasis: Clinical Review and Update Plaque Psoriasis Guttate Psoriasis Pustular Psoriasis Generalized Pustular Psoriasis Impetigo Herpetiformis Acute Generalized Exanthematous Pustulosis Localized Pustular Forms Consensus Statement of Phenotypes of Pustular Psoriasis ErythrodermicPsoriasis Manifestations of Psoriasis in Specific Locations Scalp Psoriasis Nail Psoriasis Inverse (Flexural, Intertiginous) Psoriasis Rare Forms and Some Specific Locations Pediatric Psoriasis Differential Diagnosis of Psoriasis Conclusion References 4: Psoriasis: Epidemiology, Potential Triggers, Disease Course Epidemiology Potential Triggers Trauma Infections Stress Medications Alcohol and Smoking Obesity Estrogen Disease Course References 5: Topical Therapy I: Corticosteroids and Vitamin D Analogues Topical Corticosteroids Pharmacokinetics/Mechanism of Action Vehicle Immunologic Mechanisms Use in Psoriasis Combination with Other Therapies Adverse Effects Vitamin d Analogues Structure, Biosynthesis and Mechanism of Action Calcitriol Calcipotriene (Calcipotriol) Tacalcitol Maxacalcitol Indication for Psoriasis Use with Other Treatment Modalities Adverse Effects References 6: Topical Therapy II: Retinoids, Immunomodulators, and Others Tazarotene Mechanism of Action Pharmacokinetics Toxicology Clinical Studies in Plaque Psoriasis Clinical Studies in Other Types of Psoriasis (Palmoplantar, Nail) Application Tips Topical Calcineurin Inhibitors (Immunomodulators) Pimecrolimus and Tacrolimus Mechanism of Action Toxicity Clinical Studies in Psoriasis Crisaborole 2% Ointment Tar Mechanism of Action Toxicity Clinical Studies in Psoriasis Anthralin Mechanism of Action Toxicity Clinical Studies Moisturizers and Keratolytics Conclusions References 7: Topical Therapy II: Retinoids, Immunomuodulators, and Others/Ultraviolet Therapy for Psoriasis UVB Phototherapy Dosage and Administration Efficacy Side Effects and Safety Photocarcinogenicity of UVB Phototherapy PUVA (Psoralen Plus PUVA) Dosage and Administration Efficacy Side Effects Photocarcinogenicity of PUVA Inpatient Photothearpy Goeckerman Therapy Dosage and Administration Efficacy Side Effects and Long-term Safety Ingram Therapy Non-office-based Phototherapy Commercial Tanning Therapy Home UVB Therapy Heliotherapy Climatotherapy at the Dead Sea Combination Therapy UVB and Retinoid Therapy PUVA and Retinoid Therapy UVB and Biologics Photocarcinogenicity of Combination Therapy Conclusion References 8: Laser Therapy in Psoriasis Introduction Excimer Laser Background Mechanism of Action Efficacy Safety Dosing/Protocols Other Morphologies and Special Populations Adjuvant Therapies Pulsed Dye Laser Background Mechanism of Action Efficacy Safety Other Morphologies Nd:YAG Laser Background Efficacy Carbon Dioxide Laser Background Efficacy Safety Comparative Studies References 9: Traditional Systemic Therapy I: Methotrexate and Cyclosporine Introduction Methotrexate Introduction Mechanism of Action Absorption and Bioavailability Use in Psoriasis Dosing Monitoring Guidelines Liver Biopsy Adverse Effects Hepatotoxicity Myelosuppression Pulmonary Fibrosis Drug Interactions Cyclosporine Introduction Mechanism of Action Absorption and Bioavailability Use in Psoriasis Dosing Monitoring Guidelines Adverse Effects Nephrotoxicity Hypertension Drug Interactions Summary References 10: Traditional Systemic Therapy II: Retinoids and Others Acitretin FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Hydroxyurea FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Mycophenolate Mofetil (MMF) FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence 6-Thioguanine (6TG) FDA-Approved Indication(S) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Systemic Tacrolimus FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Leflunomide FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Penicillin V and Erythromycin FDA-Approved Indication(S) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Apremilast FDA-Approved Indication(s) Mechanism of Action When Best to Use Dosage Adverse Events Recommended Monitoring Perils and Pitfalls Strength of Evidence Conclusion References Recommended Reading 11: Apremilast Bibliography 12: Etanercept Introduction Background Structure and Mechanism of Action Etanercept in the Treatment of Psoriatic Arthritis Etanercept in the Treatment of Psoriasis Combination Therapy Safety Malignancies References 13: Adalimumab for Psoriasis Introduction Adalimumab Adalimumab in Clinical Trials for Psoriasis and Psoriatic Arthritis REVEAL Champion ADEPT Adalimumab for Special Populations Pregnancy and Lactation Pediatric Elderly Fingernail Psoriasis Hidradenitis Suppurativa Generalized Pustular Psoriasis Inflammatory Bowel Disease (IBD) Hemodialysis Biologic Comparator Trials Practical Considerations for TNF-Inhibitors Safety Update Black Box Warnings: Infection and Malignancy Post-Marketing Safety Information Adalimumab Pearls Complications of Not Treating Psoriasis Conclusion References 14: Infliximab, Golimumab, and Certolizumab Pegol Introduction Mechanism of Action Efficacy for Psoriasis and Psoriatic Arthritis Infliximab Combination Therapy Golimumab Certolizumab Safety Considerations Infusion-Reactions Infection Malignancy Laboratory Data/Autoimmune Disease Dermatologic Treatment Switches Conclusion References 15: Ustekinumab Introduction Pharmacokinetics Pharmacodynamics Clinical Efficacy Psoriatic Arthritis Adolescent Patients Adverse Effects Serious Infections Malignancy Major Adverse Cardiovascular Events Other Adverse Events Laboratory Abnormalities Pregnancy and Lactation Cautions for Patients Treated with Anti-IL-12p40 Agents Conclusions References 16: Guselkumab Introduction Structure and Mechanism Pharmacodynamics and Pharmacokinetics Clinical Efficacy VOYAGE 1 VOYAGE 2 Maintenance and Recapture NAVIGATE ECLIPSE Other Studies Safety/Adverse Events Pediatrics and Breastfeeding Tuberculosis, HIV, and Live Vaccines Malignancy Inflammatory Bowel Disease Psoriatic Arthritis Hidradenitis Suppurativa Patient Controlled Injector Conclusion References 17: Tidrakizumab Introduction Rationale of Targeting IL-23 Pharmacokinetics/Pharmacodynamics Clinical Efficacy Psoriatic Arthritis Safety/Adverse Events Immunogenicity Considerations in Treatment Approach Speed of Onset Prior Treatment with Biologics Inflammatory Bowel Disease Metabolic Syndrome Withdrawal and Retreatment Pregnancy Conclusions References 18: Risankizumab Introduction Pharmacology Dosing and Monitoring Clinical Efficacy Safety Pregnancy and Lactation Conclusion References 19: Secukinumab for the Treatment of Inflammatory Skin and Joint Disease Introduction Secukinumab: Background and Pivotal Clinical Trial Data Plaque Psoriasis Difficult to Treat Psoriasis Subtypes: Palmoplantar, Nail, and Scalp Psoriasis Psoriatic Arthritis Ankylosing Spondylitis Pharmacologic Properties and Safety Future Direction of IL-17 Blockade for Chronic Inflammatory Conditions Conclusion References 20: Ixekizumab Introduction Pharmacodynamics Pharmacokinetics Clinical Efficacy Bodyweight Psoriatic Arthritis Nail Psoriasis Scalp Palmoplantar Psoriasis Genital Psoriasis Body Regions Erythrodermic and Pustular Psoriasis Adverse Effects Adverse Events of Special Interest Infections IBD Malignancy Depression Summary References 21: Brodalumab Introduction Role of IL-17 in Psoriasis Brodalumab Dosing, Storage, Administration, and Pharmacokinetics Clinical Efficacy in Plaque Psoriasis Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Clinical Efficacy in Psoriatic Arthritis Clinical Efficacy in Difficult-to-Treat Psoriasis Improvements in Quality of Life Safety and Tolerability Common Adverse Events Inflammatory Bowel Disease Serious Infections Immunizations Pregnancy Elderly Suicidal Behavior Contraindications and Cautions Initiation of Therapy Conclusion References 22: Biosimilars for Psoriasis Background Generics Versus Biosimilars Naming of Biosimilars Development of Biosimilars Approval Process Analysis of Structure and Function Nonclinical (Animal) Studies Clinical Studies Pharmacovigilance Studies Interchangeability Biosimilars in Dermatology Economic Advantage of Biosimilars Barriers to Use and Future Directions Patent Disputes and Extended Patents for Branded Drugs Prescriber Considerations Patient Factors Conclusion References 23: Research Pipeline I: Oral Therapeutics for Psoriasis Introduction JAK Inhibitors Tyk2 Inhibitor PDE4 Inhibitors RORγt Inhibitors Fumarate Esters S1P Receptor Antagonists Neurokinin-1 Receptor Antagonists Adenosine A3 Receptor Agonists H4 Receptor Antagonists IL-20/PRINS Inhibitor SYK Inhibitors Conclusion References 24: Research Pipeline II: Upcoming Biologic Therapies Introduction Overview of Pathogenesis Overview of Biologic Treatments Clinical Trial Background Psoriasis Biologics Pipeline IL-17 IL-12/23 Miscellaneous Summary References 25: Pediatric Psoriasis Introduction Epidemiology (Table 25.1) Pathogenesis Obesity and Metabolic Syndrome Diagnosis and Clinical Characteristics (Tables 25.1 and 25.3) Differential Diagnosis (Table 25.5) Biopsy and Histology Therapeutic Management (Table 25.2 and Fig. 25.6) [62] Topical Therapies Systemic Therapies (Table 25.2 and Fig. 25.6) Phototherapy Natural Supplements Dietary Recommendations Conclusions References 26: Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar Involvement Nail Psoriasis Treatment of Nail Psoriasis Treatment Approach to Nail Disease Scalp Psoriasis Clinical Presentation of Scalp Psoriasis Measuring Scalp Disease Management of Scalp Psoriasis: Topical Therapies Procedural Therapies for Scalp Psoriasis Systemic Therapy for Scalp Psoriasis Biologic Therapy for Scalp Psoriasis Treatment Algorithm for Scalp Psoriasis TNF Induced Psoriasis Palmoplantar Psoriasis References 27: Psoriasis and Comorbidities Introduction Obesity Dyslipidaemia Hypertension Non-alcoholic Fatty Liver Disease (NAFLD) Insulin Resistance and Type 2 Diabetes Mellitus Metabolic Syndrome Cardiovascular Disease (CVD) Heart Disease Evidence for an Association Between CVD and Psoriasis Evidence Against an Association Between CVD and Psoriasis Effect of Treatment of Psoriasis on CVD Risk Stroke and Atrial Fibrillation Cancer and Lymphoma Skin Cancer Lymphoma General Cancer Risk Autoimmune Disease Psychiatric Illness Conclusions References 28: Summary of Published Treatment Guidelines Introduction Methods Overview of Treatment Guidelines General Principles Topicals Corticosteroids Vitamin D Derivatives Tazarotene Topical Calcineurin Inhibitors Anthralin Coal Tar Phototherapy and Photochemotherapy Systemics Non-biologic systemics Acitretin Cyclosporine A Methotrexate Apremilast Systemic Corticosteroids Other Systemic Medications Biologics Adalimumab Etanercept Infliximab Ustekinumab Secukinumab Considerations for Less Common Psoriasis Types Pustular Erythrodermic Flexural/Inverse Considerations for Specific Patient Populations Pregnancy Children Limitations Conclusion References Index
